Treatment scale-up to achieve global HCV incidence and mortality elimination targets: A cost-effectiveness model

Gut

Volumn 66, Issue 8, 2017, Pages 1507-1515

  Scott, Nick ^a,b   McBryde, Emma S ^a,c,d   Thompson, Alexander ^d,e   Doyle, Joseph S ^a,e,f   Hellard, Margaret E ^a,b,g  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c JAMES COOK UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^g ALFRED HOSPITAL   (Australia)

Author keywords

COST EFFECTIVENESS; EPIDEMIOLOGY; HEPATITIS C

Indexed keywords

ARTICLE; AUSTRALIA; COMPARTMENT MODEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DISEASE COURSE; DISEASE ELIMINATION; HEALTH CARE COST; HEALTH CARE PLANNING; HEPATITIS C; INTRAVENOUS DRUG ABUSE; LIVER DISEASE; MATHEMATICAL MODEL; MONTE CARLO METHOD; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; SCALE UP; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; ADULT; AGED; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; GLOBAL HEALTH; HARM REDUCTION; HUMAN; INCIDENCE; MIDDLE AGED; MOTIVATION; PREVALENCE; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; COST-BENEFIT ANALYSIS; GLOBAL HEALTH; GOALS; HARM REDUCTION; HEALTH CARE COSTS; HEPATITIS C; HUMANS; INCIDENCE; MIDDLE AGED; MODELS, ECONOMIC; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; SUBSTANCE ABUSE, INTRAVENOUS; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84964626319     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-311504     Document Type: Article

References (31)

1. Burki T. Elimination on the agenda for hepatitis C. Lancet Infect Dis 2014;14: 452-3.
2. World Health Organisation. Draft global health sector strategy on viral hepatitis, 2016-2021-the first of its kind. 2015. http://wwwwhoint/hepatitis/news-events/ strategy2016-2021/en/
3. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2014. The University of New South Wales, Sydney NSW 2052, 2014.
4. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67.
5. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-62.
6. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-83.
7. Iversen J, Maher L. Australian Needle and Syringe Program National Data Report 2008-2012. The Kirby Institute, University of New South Wales. ISBN: 1448-5915, 2013.
8. Ministerial Advisory Committee on AIDS Sexual Health and Hepatitis. Hepatitis C Virus Projections Working Group: Estimates and Projections of the Hepatitis C Virus Epidemic in Australia. 2006.
9. Dore GJ. The changing therapeutic landscape for hepatitis C. Med J Aust 2012;196:629-32.
10. Walsh N, Lim M, Hellard M. Using a surveillance system to identify and treat newly acquired hepatitis C infection. J Gastroenterol Hepatol 2008;23:1891-4.
11. Grebely J, Oser M, Taylor LE, et al. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis 2013;207(Suppl 1):S19-25.
12. Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013;58:1598-609.
13. Sievert W, Razavi H, Estes C, et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol 2014;29(Suppl 1):1-9.
14. Hellard ME, Jenkinson R, Higgs P, et al. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust 2012;196:638-41.
15. Scott N, Iser D, Thompson A, et al. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. J Gastroenterol Hepatol 2015.[online ahead of print] doi:10.1111/jgh.13223
16. Simmons B, Saleem J, Hill A, et al. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 2016;62:683-94.
17. Scott N, McBryde E, Vickerman P, et al. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med 2015;13:198.
18. Scott N, Hellard M, McBryde E. Modelling hepatitis C virus transmission among people who inject drugs: assumptions, limitations and future challenges. Virulence 2016;7:201-8.
19. Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 2011;274:58-66.
20. Vickerman P, Martin N, Hickman M. Can Hepatitis C virus treatment be used as a prevention strategy Additional model projections for Australia and elsewhere. Drug Alcohol Depend 2011;113:83-5; discussion 86-7.
21. Kwon JA, Anderson J, Kerr CC, et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. Aids 2012;26:2201-10.
22. Vickerman P, Martin N, Turner K, et al. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence Model projections for different epidemic settings. Addiction 2012;107:1984-95.
23. Australian Government Department of Health. https://www.health.gov.au/internet/ ministers/publishing.nsf/Content/health-mediarel-yr2015-ley154.htm (December 2015).
24. Pharmaceutical Benefits Advisory Committee (PBAC). November 2015. Positive Recommendations, http://www.pbs.gov.au/info/industry/listing/elements/ pbac-meetings/pbac-outcomes/recommendations-pbac-november-2015
25. Wade AJ, Macdonald D, Doyle JS, et al. Successful community based treatment of hepatitis C in people who inject drugs. PLoS ONE 2015;10.
26. Archer G, Buring M, Clark B, et al. Prevalence of hepatitis C virus antibodies in Sydney blood donors. Med J Aust 1992;157:225-7.
27. Ismay SL, Thomas S, Fellows A, et al. Post-transfusion hepatitis revisited. Med J Aust 1995;163:74-7.
28. Mison L, Young I, O'Donoghue M, et al. Prevalence of hepatitis C virus and genotype distribution in an Australian volunteer blood donor population. Transfusion 1997;37:73-8.
29. Wong P, Dodd R, Kiely P, et al. Characteristics of hepatitis C-positive blood donors in Victoria, Australia. Transfus Med 1999;9:15-19.
30. Leidner AJ, Chesson HW, Xu F, et al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015;61:1860-9.
31. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009;49:561-73.